Home Cart Sign in  
Chemical Structure| 356547-88-1 Chemical Structure| 356547-88-1

Structure of Belimumab
CAS No.: 356547-88-1

Chemical Structure| 356547-88-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Belimumab is a humanized IgG1 monoclonal antibody that inhibits BLyS by preventing its binding to receptors. Belimumab has potential for systemic lupus erythematosus research.

Synonyms: LymphoStat B

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Belimumab

CAS No. :356547-88-1
M.W : 144.54 kDa
SMILES Code : NONE
Synonyms :
LymphoStat B
MDL No. :N/A

Safety of Belimumab

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Isoform Comparison

Biological Activity

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Long Evans rats Intermittent ocular hypertension model (iOHT) Intravenous administration 10 mg/kg Weekly for 6 weeks To evaluate the effect of Belimumab on retinal ganglion cell and optic nerve axon loss induced by intermittent ocular hypertension. Results showed Belimumab treatment only slightly improved axonal survival and reduced serum IgG concentration but had limited impact on neurodegeneration. J Neuroinflammation. 2016 Apr 18;13(1):82
Mice Acute graft-versus-host disease (GVHD) model Intraperitoneal injection 200 μg Twice a week, until day 17 post-BMT To evaluate the therapeutic effect of belimumab on acute GVHD. Results showed that belimumab treatment reduced the proportion of CD4+IL-17+ cells and increased the proportion of CD4+CD25+Foxp3+ Treg cells at day 17 post-BMT, improving GVHD scores. Additionally, belimumab modulated B-cell subsets, increasing mature B cells and decreasing memory B cells and plasma cells. Front Immunol. 2022 Dec 6;13:995149
Human Systemic lupus erythematosus patients Intravenous 10 mg/kg Monthly for more than 7 years To investigate the effects of Belimumab on B cells in systemic lupus erythematosus patients, results showed that Belimumab treatment led to approximately 90% depletion of naive B cells and 60%-95% deletion of all other B cell subsets. JCI Insight. 2018 Sep 6;3(17):e122525

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT05585671 Whether Belimumab Could Reduce... More >> 2-year Risk of New-onset Lupus Nephritis Less << NOT_YET_RECRUITING 2026-06-01 -
NCT03591380 Kidney Transplantation PHASE2 TERMINATED 2021-12-03 University of Wisconsin Hospit... More >>als and Clinics, Madison, Wisconsin, 53792, United States Less <<
NCT06327724 Systemic Lupus Erythematosus RECRUITING 2025-03-01 Amsterdam UMC; location Academ... More >>ic Medical Center, Amsterdam, 1100DD, Netherlands Less <<
NCT01142011 Symptomatic Waldenstroms Macro... More >>globulinaemia Less << PHASE2 UNKNOWN 2025-01-13 The Peter MacCallum Cancer Cen... More >>tre, Melbourne, Victoria, 3002, Australia|Alfred Health, Melbourne, Victoria, 3181, Australia Less <<
NCT01597622 Systemic Lupus Erythematosus PHASE3 COMPLETED 2018-09-13 GSK Investigational Site, Chib... More >>a, 275-8580, Japan|GSK Investigational Site, Ehime, 791-0295, Japan|GSK Investigational Site, Fukuoka, 807-8555, Japan|GSK Investigational Site, Fukuoka, 810-8563, Japan|GSK Investigational Site, Hiroshima, 730-8619, Japan|GSK Investigational Site, Hiroshima, 739-0002, Japan|GSK Investigational Site, Hokkaido, 060-8604, Japan|GSK Investigational Site, Hokkaido, 060-8648, Japan|GSK Investigational Site, Hyogo, 675-8545, Japan|GSK Investigational Site, Miyagi, 980-8574, Japan|GSK Investigational Site, Nagasaki, 857-1195, Japan|GSK Investigational Site, Okayama, 710-8522, Japan|GSK Investigational Site, Okinawa, 901-0243, Japan|GSK Investigational Site, Tochigi, 321-0293, Japan|GSK Investigational Site, Tokyo, 104-8560, Japan|GSK Investigational Site, Tokyo, 113-8431, Japan|GSK Investigational Site, Tokyo, 160-8582, Japan|GSK Investigational Site, Tokyo, 162-8655, Japan|GSK Investigational Site, Busan, 602-715, Korea, Republic of|GSK Investigational Site, Busan, Korea, Republic of|GSK Investigational Site, Daegu, 700-721, Korea, Republic of|GSK Investigational Site, Incheon, 400-711, Korea, Republic of|GSK Investigational Site, Seoul, 110-744, Korea, Republic of|GSK Investigational Site, Seoul, 133-792, Korea, Republic of|GSK Investigational Site, Seoul, 137-701, Korea, Republic of|GSK Investigational Site, Seoul, 150-713, Korea, Republic of|GSK Investigational Site, Suwon, Kyonggi-do, 443-721, Korea, Republic of Less <<
NCT04893161 Systemic Lupus Erythematosus PHASE4 NOT_YET_RECRUITING 2026-01-31 -
NCT03207958 Graft Vs Host Disease|Graft-ve... More >>rsus-host-disease Less << PHASE1 COMPLETED 2024-02-09 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT06716606 Bronchial Diseases PHASE3 RECRUITING 2030-01-08 GSK Investigational Site, Ciud... More >>ad Autonoma Buenos Aires, C1015ABO, Argentina|GSK Investigational Site, Yongsan-Ku Seoul, Korea, Republic of Less <<
NCT02880852 Systemic Lupus Erythematosus PHASE1 COMPLETED 2017-09-08 GSK Investigational Site, Shan... More >>ghai, China|GSK Investigational Site, Suzhou, 215004, China Less <<
NCT01025193 Desensitization PHASE2 TERMINATED 2025-11-11 University of Pennsyvlania Kid... More >>ney Transplant Program, Philadelphia, Pennsylvania, 19104, United States Less <<
NCT01160666 Sj?gren's Syndrome PHASE2 COMPLETED 2025-06-12 Assistance Publique - H?pitaux... More >> de Paris : BICETRE Hospital, Le Kremlin Bicêtre, 94275, France Less <<
NCT05020782 Antiphospholipid Syndrome PHASE2|PHASE3 UNKNOWN 2025-01-01 San Giovanni Bosco Hospital, T... More >>urin, Piedmont, 10154, Italy Less <<
NCT05154734 NMO Spectrum Disorder PHASE1|PHASE2 COMPLETED 2024-04-09 Tianjin Medical University Gen... More >>eral Hospital, Tianjin, Tianjin, 300052, China Less <<
NCT04570306 Systemic Lupus Erythematosus COMPLETED 2023-12-16 BRFAA, Athens, 11527, Greece
NCT02119156 Systemic Lupus Erythematosus PHASE3 COMPLETED 2018-12-14 GSK Investigational Site, Los ... More >>Angeles, California, 90048, United States|GSK Investigational Site, Manhasset, New York, 11030, United States|GSK Investigational Site, Dallas, Texas, 75246, United States|GSK Investigational Site, Hefei, Anhui, 230001, China|GSK Investigational Site, Suzhou, Jiangsu, 215006, China|GSK Investigational Site, Hangzhou, Zhejiang, 310009, China|GSK Investigational Site, Beijing, 100032, China|GSK Investigational Site, Beijing, 100044, China|GSK Investigational Site, Chiba, 275-8580, Japan|GSK Investigational Site, Ehime, 791-0295, Japan|GSK Investigational Site, Hokkaido, 060-8604, Japan|GSK Investigational Site, Miyagi, 980-8574, Japan|GSK Investigational Site, Nagasaki, 857-1195, Japan|GSK Investigational Site, Tokyo, 104-8560, Japan|GSK Investigational Site, Tokyo, 162-8655, Japan|GSK Investigational Site, Daegu, 700-721, Korea, Republic of|GSK Investigational Site, Seoul, 110-744, Korea, Republic of|GSK Investigational Site, Seoul, 133-792, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Suwon, Kyonggi-do, 443-721, Korea, Republic of Less <<
 

Historical Records

Categories